CSF amyloid-beta 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
2008 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
CSF amyloid-beta 1-38 and 1-42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction
Bibl, M.; Lewczuk, P.; Esselmann, H.; Mollenhauer, B.; Klafki, H.-W.; Welge, V. & Wolf, S. et al. (2008)
PROTEOMICS - CLINICAL APPLICATIONS, 2(10-11) pp. 1548-1556. DOI: https://doi.org/10.1002/prca.200800006
Documents & Media
Details
- Authors
- Bibl, Mirko; Lewczuk, Piotr; Esselmann, Hermann; Mollenhauer, Brit; Klafki, Hans-Wolfgang; Welge, Volker; Wolf, Stefanie; Trenkwalder, Claudia; Otto, Markus; Kornhuber, Johannes; Wiltfang, Jens
- Abstract
- Cerebrospinal fluid (CSF) A beta I-38, A beta 1-40, and A beta 1-42 were comparatively analyzed by amyloid-beta SDS-PAGE with Western immunoblot (A beta-SDS-PAGE/immunoblot), electrochemiluminescence detection and ELISA (MSD/ELISA) in patients with Alzheimer's disease (AD, n = 40), frontotemporal dementia (FTD, n = 30), and other dementias (n = 50) and nondemented disease controls (n = 30). CSF A beta-peptide concentrations were higher and selective decreases of CSF A beta 1-38 in FTD and A beta 1-42 in AD were more evident as measured after SDS-denaturizing of samples by A beta-SDS-PAGE/immunoblot. The SDS-accessible pool of CSF A beta 1-38 and A beta 1-42, represented by the individual gain of A beta-peptide yield using A beta-SDS-PAGE/immunoblot, was reduced in both FTD and AD. Accordingly, biomarker accuracies of A beta 1-38 and A beta 1-42 for detection of FTD and AD, respectively declined as determined by MSD/ELISA. We conclude that a pool of CSF A beta 1-38 and A beta 1-42, which shows disease-specific reductions in FTD and AD, may be bound to carriers and can be released by SDS. Assessing this SDS-accessible A beta-peptide pool may crucially enhance the accuracy of CSF biomarker tests. Identifying disease-specific binding properties of affected A beta carriers may elucidate pathogenic aspects and open up a novel field for therapeutic approaches.
- Issue Date
- 2008
- Status
- published
- Publisher
- Wiley-v C H Verlag Gmbh
- Journal
- PROTEOMICS - CLINICAL APPLICATIONS
- ISSN
- 1862-8346